RxDoctor Payments DataLook up a doctor →

Stephanie Blank, MD

Gynecologic Oncology · New York, NYNPI 1043211626

Payments from drug & device makers

$3,318,930in general payments, 2019–2025

Across 482 payments — averaging $6885.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$1.3M
  • GSK$564K
  • Seagen Inc.$416K
  • Genentech, Inc.$351K
  • AstraZeneca$268K
  • Tesaro, Inc.$122K
  • plus $267K from 8 others
$461in research payments, 2019–2025

Across 2 payments — averaging $230.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$461

What the payments were for

  • Food & beverage$22976%
  • Education$7124%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck153$1,331,622
GSK122$563,669
Seagen Inc.102$415,717
Genentech, Inc.51$350,868
AstraZeneca1$267,910
Tesaro, Inc.7$122,323
AbbVie11$111,726
Pfizer7$50,234
EMD Serono, Inc.15$44,230
Immunogen, Inc.5$39,200
Astrazeneca UK Limited2$15,508
Daiichi Sankyo Inc.2$5,675
Biontech SE1$153
Intuitive Surgical3$95

How this compares

$3,318,930 in reported general payments places this provider in the 95th percentile of 154 gynecologic oncology providers in New York.

See all gynecologic oncology providers in New York

Medicare billing

Part B allowed, 2024
$42,321
Medicare patients
116
Services billed
339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →